Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia

The treatment landscape for chronic lymphocytic leukemia (CLL) has been transformed by the availability of Bruton's tyrosine kinase inhibitors (BTKis) and the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax. Despite clinical trial data supporting these novel oral agents, evidence evaluating real...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2023-12, Vol.64 (14), p.2316-2323
Main Authors: Huntington, Scott F, Manzoor, Beenish S, Puckett, Justin T, Kamal-Bahl, Sachin, Alhasani, Hasan, Ravelo, Arliene, Jawaid, Dureshahwar, Doshi, Jalpa A
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Agents - therapeutic use
Bridged Bicyclo Compounds, Heterocyclic - therapeutic use
Humans
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell - pathology
Lymphoma, B-Cell - drug therapy
Medicare
Recurrence
United States - epidemiology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The treatment landscape for chronic lymphocytic leukemia (CLL) has been transformed by the availability of Bruton's tyrosine kinase inhibitors (BTKis) and the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax. Despite clinical trial data supporting these novel oral agents, evidence evaluating real-world adherence is limited. This study used 2015-2019 Medicare claims data for elderly patients with relapsed/refractory CLL to assess differences in real-world adherence and discontinuation in the 12 months after treatment initiation. In the final sample of 711 venetoclax patients and 1,566 BTKi patients, we found that those initiating venetoclax tended to be younger (mean age 75.6 [SD 6.0] vs 77.6 [SD 6.9] years,  
ISSN:1042-8194
1029-2403
1029-2403
DOI:10.1080/10428194.2023.2255326